news & events - latest news and happenings in the SCD community | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
https://www.onescdvoice.com/wp-content/uploads/2018/06/GBT.png
clinical trials and research

GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell disease

Global Blood Therapeutics, Inc. today announced the completion of a planned review of Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, which is evaluating voxelotor for the treatment of sickle cell disease (SCD). On the primary endpoint (the proportion of patients with greater than 1 g/dL increase in hemoglobin versus baseline), a statistically significant increase was demonstrated with voxelotor at both the 1500 mg and 900 mg doses after 12 weeks of treatment versus placebo.

The independent Data and Safety Monitoring Board (DSMB) completed its most recent clinical safety review in May 2018 and did not identify safety concerns with voxelotor at either dose level across all patients dosed in the ongoing SCD clinical program, including adult patients in the Phase 3 HOPE Study and adolescent patients in the HOPE-KIDS 1 (GBT440-007) Study. The DSMB supported the initiation of dosing in children as young as age 4.

Jun 27, 2018
https://www.onescdvoice.com/wp-content/uploads/2018/07/scfa.png
happenings

Sickle Cell Anemia & Thalassaemia: An International Biomedical-Sociocultural Conference 2018

The Faculty of Dentistry, Medicine and Pharmacy in conjunction with Sickle Cell Foundation of Alberta invites you to join us for the 2018 (Re) imagining Health: Sickle Cell Anemia & Thalassaemia: An International Biomedical-Sociocultural Conference.

The purpose of the conference is to bring together multiple voices to support and build inclusive an equitable teaching and learning environments for medical staff, sickle cell disease patients, their families, first responders the public and other stakeholders. The event will be targeted towards patients and their families, physicians, surgeons, researchers and other medical practitioners within the community committed to finding a cure for Sickle Cell Anemia and more knowledge of the continued effects of sickle cell anemia trait.

 

Date:

November 16 – 17, 2018

 

Venue:

Edmonton Clinic Health Academy, University of Alberta

11405 87 Ave NW, Edmonton, Alberta, Canada

Nov 16, 2018